IXICO TECHNOLOGIES LIMITED

Their core work

IXICO is a London-based health technology SME specializing in digital biomarkers and data analytics for neurodegenerative diseases, particularly Alzheimer's disease and dementia. They provide imaging analysis platforms, real-world evidence generation, and longitudinal data management services for clinical research. Their work bridges the gap between clinical trial data and actionable patient outcomes, serving pharmaceutical companies and academic research consortia studying cognitive decline and sensory impairment in aging populations.

What they specialise in

How they've shifted over time

All three projects started in 2016, so the evolution is better read through thematic scope rather than strict chronology. Early keywords emphasize broad mental health, sensory impairment, and quality-of-life screening for the elderly (SENSE-Cog). The later-period keywords shift toward more targeted Alzheimer's-specific work — amyloid imaging, disease modelling, and health economics (AMYPAD, ROADMAP). This suggests a trajectory from general geriatric health toward specialized neurodegeneration analytics.

IXICO is deepening its focus on Alzheimer's-specific data platforms and real-world evidence, positioning itself as a specialist analytics provider for dementia drug development and clinical trials.

How they like to work

IXICO operates exclusively as a participant, never coordinating — consistent with their role as a specialist technology and analytics provider embedded in larger research consortia. With 57 unique partners across 15 countries from just 3 projects, they work in large, multi-national consortia typical of IMI (Innovative Medicines Initiative) and major health research programs. This makes them an accessible partner: experienced in complex consortia dynamics and used to delivering defined technical contributions within big teams.

Despite only 3 projects, IXICO has built a broad network of 57 partners across 15 countries, reflecting participation in large health research consortia that typically include pharma companies, hospitals, and universities across Europe.

What sets them apart

IXICO occupies a rare niche as a commercial SME providing imaging analytics and data platform services specifically for neurodegenerative disease research. Unlike academic partners who contribute scientific expertise, IXICO brings productized data management and analysis capabilities — making them a practical choice when a consortium needs a technology partner to handle imaging data, build longitudinal databases, or generate real-world evidence. Their commercial orientation means they can deliver sustained, professional-grade platform services beyond the life of a single project.

Highlights from their portfolio

• AMYPAD
  Largest funding (EUR 1.2M to IXICO) — focused on amyloid imaging to prevent Alzheimer's, indicating IXICO's core data analytics contribution to a major IMI initiative.
• ROADMAP
  Directly built a multimodal data access platform for Alzheimer's real-world outcomes — the closest match to IXICO's commercial product offering.
• SENSE-Cog
  Broadest scope project linking hearing/vision impairment to dementia, though IXICO's minimal funding (EUR 7,245) suggests a very limited or data-advisory role.